Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sabatolimab (MBG453)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

TIM-3 antagonist

Related drugs:

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	MBG453 Sensitive: B - Late Trials MBG453 Sensitive : B	MBG453 Sensitive: B - Late Trials MBG453 Sensitive : B
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3	MBG453 Sensitive: C3 – Early Trials MBG453 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	azacitidine + MBG453 Sensitive: C3 – Early Trials azacitidine + MBG453 Sensitive : C3	azacitidine + MBG453 Sensitive: C3 – Early Trials azacitidine + MBG453 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine + MBG453 Sensitive: C3 – Early Trials decitabine + MBG453 Sensitive : C3	decitabine + MBG453 Sensitive: C3 – Early Trials decitabine + MBG453 Sensitive : C3
MECOM rearrangement	Myelodysplastic Syndrome	MECOM rearrangement	Myelodysplastic Syndrome	MBG453 Sensitive: C4 – Case Studies MBG453 Sensitive : C4	MBG453 Sensitive: C4 – Case Studies MBG453 Sensitive : C4